 |
BioWorld-International-2002-07-31
BresaGen, British Biotech See Setbacks Continue As E21R Fails
BresaGen, British Biotech See Setbacks Continue As E21R Fails
SYDNEY, Australia - Unfavorable results from clinical trials have stopped another collaborative project involving an Australian biotech company, despite favorable preclinical trials. BresaGen Ltd. and British Biotech plc abandoned a collaborative agreement to develop E21R as a treatment for acute myeloid leukemia (AML). (BioWorld International)